Orkla ASA

ORK

Equity

ISIN NO0003733800 / Valor 599441

Oslo Stock Exchange (2026-02-24)

NOK 130.50+0.23%

Orkla ASA
UMushroom community rating:

4.33 3 votes No rating yet

NegativeNeutralPositive

About company

Orkla ASA is a prominent Norwegian investment company that focuses on consumer-oriented brands and businesses. The company manages a diverse portfolio of approximately ten subsidiaries operating in sectors such as food, personal care, and household products. By leveraging its extensive brand portfolio, Orkla delivers a wide range of consumer goods across the Nordic and Baltic regions. The company emphasizes strategic investments and effective management to maintain its significant presence in the consumer market, ensuring steady growth and sustained market relevance.

Summarized from source with an LLMView SourceSector: Consumer Non-Cyclicals

Key financials (Q3 2025)

Operating revenues: NOK 17,946m (Q3‑24: 17,209m, +4%). Adjusted EBIT (Consolidated Portfolio Companies): NOK 2,098m (≈ +1% vs Q3‑24). Adjusted EBIT (group incl. Orkla ASA & Business Services): NOK 2,039m (+2%). Reported EBIT: NOK 1,638m (Q3‑24: 1,258m). Profit before tax: NOK 1,997m. Profit for the period: NOK 1,692m.

Earnings per share

Adjusted EPS (diluted): NOK 1.85 (Q3‑24: 1.70, +9%). Reported EPS (diluted): NOK 1.57 (Q3‑24: 1.18).

Organic growth and drivers

Organic growth for the consolidated portfolio companies was 4.4% in Q3‑2025. Growth was driven by a mix of volume/mix and price across clusters, with positive contributions in several segments despite some negative currency effects noted by management.

Segment highlights

Jotun: strong revenue and EBITA improvement (excluding currency effects). Orkla Foods: modest sales growth, improving market share but some temporary delivery issues. Orkla Snacks: strong organic sales growth but underlying EBIT pressure (cocoa/chocolate market and commodity effects). Orkla Home & Personal Care: good volume/mix growth and EBIT improvement. Orkla Food Ingredients: solid volume/price dynamics (plant‑based growth) with mixed cluster performance. Orkla Health: double‑digit organic growth but EBIT decline due to margin pressure and higher SG&A/marketing.

Cash flow and balance sheet

YTD cash flow from operations: NOK 4.8 billion (YTD‑24: 5.2bn). Cash flow before capital allocation: NOK 4.1 billion. Net interest‑bearing debt was around NOK 16.0 billion at 30.09.2025, with leverage ~1.7x EBITDA.

Capital allocation & corporate actions

Orkla initiated a NOK 4.0 billion share buyback programme (to commence 17 November 2025 and run until no later than 31 December 2026). Q3 also included the IPO of Orkla India and management reiterated priorities of M&A/growth investments, returning excess capital to shareholders and maintaining a stable dividend.

Summarized from source with an LLMView Source

Key figures

20.8%1Y

87.8%3Y

62.4%5Y

Performance

20.3%1Y

31.6%3Y

26.8%5Y

Volatility